| Publication | Date of Publication | Type |
|---|
| Joint modelling of a binary and a continuous outcome measured at two cycles to determine the optimal dose | 2024-11-21 | Paper |
| Minimization in randomized clinical trials | 2024-06-23 | Paper |
| Generalized pairwise comparisons for censored data: an overview | 2024-06-05 | Paper |
| Evaluation of Laplace distribution-based ANOVA models applied to microarray data | 2020-09-30 | Paper |
| A Version of the EM Algorithm for Proportional Hazard Model with Random Effects | 2020-09-24 | Paper |
| Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes | 2020-09-22 | Paper |
| A multivariate linear model for investigating the association between gene-module co-expression and a continuous covariate | 2019-09-12 | Paper |
| Sequential double cross-validation for assessment of added predictive ability in high-dimensional omic applications | 2018-11-15 | Paper |
| Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials | 2018-08-14 | Paper |
| Estimation of diagnostic accuracy of a combination of continuous biomarkers allowing for conditional dependence between the biomarkers and the imperfect reference‐test | 2017-07-21 | Paper |
| An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference | 2016-10-12 | Paper |
| Statistical evaluation of surrogate endpoints with examples from cancer clinical trials | 2016-03-14 | Paper |
| On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints | 2016-01-22 | Paper |
| A hidden Markov-model for gene mapping based on whole-genome next generation sequencing data | 2015-02-26 | Paper |
| A Markov-chain model for the analysis of high-resolution enzymatically \(^{18}\)O-labeled mass spectra | 2014-10-07 | Paper |
| Simplified modeling strategies for surrogate validation with multivariate failure-time data | 2014-04-14 | Paper |
| A cross-validation study to select a classification procedure for clinical diagnosis based on proteomic mass spectrometry | 2013-12-05 | Paper |
| A Markov-chain-based regression model with random effects for the analysis of18O-labelled mass spectra | 2013-06-03 | Paper |
| Linear Mixed-Effects Models Using R | 2013-02-22 | Paper |
| Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time | 2012-06-27 | Paper |
| A Comparison of Procedures for Controlling the False Discovery Rate in the Presence of Small Variance Genes: A Simulation Study | 2009-12-16 | Paper |
| Exploring and validating surrogate endpoints in colorectal cancer | 2009-07-13 | Paper |
| Comparison of different estimation procedures for proportional hazards model with random effects | 2009-05-29 | Paper |
| Choice of units of analysis and modeling strategies in multilevel hierarchical models | 2008-11-26 | Paper |
| Fitting Conditional Survival Models to Meta‐Analytic Data by Using a Transformation Toward Mixed‐Effects Models | 2008-10-15 | Paper |
| Performance of Gene Selection and Classification Methods in a Microarray Setting: A Simulation Study | 2008-03-18 | Paper |
| The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials | 2008-03-11 | Paper |
| Testing for Trends in Dose-Response Microarray Experiments: A Comparison of Several Testing Procedures, Multiplicity and Resampling-Based Inference | 2008-02-18 | Paper |
| Using Linear Mixed Models for Normalization of cDNA Microarrays | 2008-02-18 | Paper |
| A perspective on surrogate endpoints in controlled clinical trials | 2007-11-05 | Paper |
| Validation of a longitudinally measured surrogate marker for a time-to-event endpoint | 2007-09-11 | Paper |
| Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints | 2007-06-11 | Paper |
| Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points | 2007-05-30 | Paper |
| Resampling Plans for Frailty Models | 2006-08-10 | Paper |
| Simplified hierarchical linear models for the evaluation of surrogate endpoints | 2003-10-29 | Paper |
| Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points | 2001-12-01 | Paper |
| The validation of surrogate endpoints in meta-analyses of randomized experiments | 2000-07-11 | Paper |
